SENTIS™ – Oncology

BGI SENTIS™ Hereditary Cancer Panel

BGI’s hereditary risk screening cancer panels target genes previously linked to a predisposition of cancer. Panel selection was based on expert curation of scientific literature and other high quality resources, including formal medical guidelines.

BGI’s Comprehensive Hereditary Cancer Panels provides information on 79 genes associated with 24 different types of hereditary cancer including some of the most commonly occurring cancers such as hereditary breast, ovarian, colorectal, pancreatic, prostate, and stomach cancer. BGI detects different alterations including germline SNV, Indels, and CNV.

Product Name
Test Content
Sentis Hereditary Cancer Panel (Female) 74 Genes 23 Cancer Types
Sentis Hereditary Cancer Panel (Male) 79 Genes 22 Cancer Types
Sentis Hereditary Breast and Ovarian Cancer 2 Genes/26 Genes
Sentis Hereditary Colorectal Cancer 23 Genes
Sentis Hereditary Prostate Cancer 23 Genes
Sentis Hereditary Pancreatic Cancer 12 Genes
Sample Type
Sample Volume / Concentration
Saliva ≥ 2 mL
Peripheral blood ≥ 5 mL
Good quality DNA ≥ 3µg

BGI SENTIS™ Cancer Precision Medicine Discovery

BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.

BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions. Both tissue samples and liquid biopsy samples are supported.

1) BGI SENTIS™ Lung Cancer Panel

BGI’s lung cancer panel covers 11 genes with direct therapeutic implications for 20 targeted drugs, including those recommended in the latest NCCN guidelines. The panel detects all classes of genomic alterations including SNV, CNV, InDels and Fusion using routine FFPE samples, tumor tissue, DNA or peripheral blood.

Genes
Mutation Types
Genes
Mutation Types
AKT1* SNV KRAS SNV
ALK Fusion, CNV,SNV MAP2K1 SNV
BRAF SNV MET Indel, CNV
DDR2* SNV NRAS SNV
EGFR SNV, Indel, CNV NTRK1 Fusion
ERBB2 Indel, CNV PIK3CA SNV
FBXW7* SNV PTEN* SNV
FGFR3 Fusion RET Fusion
HRAS* SNV ROS1 SNV, Fusion
KIT* SNV TP53* SNV

*Genes not included for liquid biopsy

Panels
Sample Requirements

SENTIS™ Lung Cancer Panel

(Tissue, 20 genes)

60 mg tissue

or

10 FFPE 10 mm*10 mm (5-10 μm) sections

or

2-3 samplings of biopsy or ≥ 500 ng good quality, tumor DNA

SENTIS™ Non-invasive Lung Cancer Panel

(ctDNA, 13 genes)

≥ 8mL of peripheral blood (separated plasma and formed elements)

or

≥ 8mL of peripheral blood collected in Streck Cell-Free DNA BCT® tube

2) BGI SENTIS™ Cancer+ Discovery Panel

BGI’s Cancer+ Discovery Panel is designed to identify all classes of actionable genomic alterations, including SNP, CNV, InDels and Fusions, across a total of 508 cancer-related genes. Results are supported by in depth mutation analysis and pharmacogenomics information relating to 102 cancer therapeutics approved by the FDA or currently undergoing clinical trials.

PanelsSample Requirements

BGI SENTIS™ Cancer+Discovery

(Tissue)

60 mg tissue

or

15 FFPE 10 mm*10 mm (5-10 μm) sections

or

≥ 3 samplings of biopsy

or

≥ 3μg good quality, tumor DNA

5mL of peripheral blood
BGI SENTIS™ Cancer+Discovery (ctDNA)

≥ 10mL of peripheral blood (separated plasma and formed elements)

or

≥ 8mL of peripheral blood collected in Streck Cell-Free DNA BCT® tube

3) BGI SENTIS™ HPV Test

Human papilloma virus (HPV) infection is associated with nearly all of cervical cancer cases (99.7%) worldwide[1] . Identification of HPV is an important tool for screening and prevention of carcinoma of the cervix. The BGI HPV Test combines self-sampling technology and genotyping assay to detect 14 most important, “high-risk” types of HPV, including HPV -16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 2 “low-risk” types of the virus, HPV -6, 11. In many parts of the world, HPV testing has replaced Pap smear test as the primary screening test for cervical cancer.

 

14 “high-risk” types of HPV

HPV -16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

2 “low-risk” types of HPV

HPV -6, 11

Sample typeStorage mediaQuantity & QualityStorage & Shipment
Cervical exfoliated cellsPE tube≥ 2.5mL, with visible turbidity.Stored and shipped at 2-8°C, reaching BGI lab within 7 days.
CardSample region turns to be white form purple.Stored and shipped at room temperature, reaching BGI lab within 7 days.
DNA (extracted from exfoliated cells)DNA extraction and purification protocol, and composition of storing buffer (such as TE or ddH2O) are required. The storing buffer cannot contain SDS.

Concentration: 25ng/µL,

Volume: ≥ 20 µL OD260/280: 1.8-2.0, no degradation.

Stored and shipped at low temperature, and reaching BGI lab within 7 days with dry ice or icebags. Use enough dry ice to prevent it from complete sublimation before arrival.

[1] Tanjila Rahman, Shahina Tabassum, Munira Jahan, et al. Risk of Cervical Cancer Associated with HPV Infection among the Gynae Outdoor Patients. Bang Med J (Khulna) 2013; 46:3-6.